Article

Reduction of immune activation with chloroquine therapy during chronic HIV infection

Human Immunology Section, NIH Vaccine Research Center, Bethesda, MD 20892-3005, USA.
Journal of Virology (Impact Factor: 4.65). 11/2010; 84(22):12082-6. DOI: 10.1128/JVI.01466-10
Source: PubMed

ABSTRACT Increased levels of activated T cells are a hallmark of the chronic stage of human immunodeficiency virus (HIV) infection and are highly correlated with HIV disease progression. We evaluated chloroquine (CQ) as a potential therapy to reduce immune activation during HIV infection. We found that the frequency of CD38(+) HLA-DR(+) CD8 T cells, as well as Ki-67 expression in CD8 and CD4 T cells, was significantly reduced during CQ treatment. Our data indicate that treatment with CQ reduces systemic T-cell immune activation and, thus, that its use may be beneficial for certain groups of HIV-infected individuals.

Download full-text

Full-text

Available from: William M Stauffer, Aug 10, 2015
0 Followers
 · 
136 Views
  • Source
    • "So far, studies employing these and other anti-inflammatory molecules have rendered contrasting results (Hatano, 2013). Thus, chloroquine administration has been shown to decrease levels of T cell activation (Murray et al., 2010) but produce faster CD4þ T cell loss when used for longer periods of time (Paton et al., 2012). A better knowledge of the best timing to implement interventions aimed at decreasing persistent immune activation is warranted. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Thirty years after the identification of HIV, a cure for HIV infection is still to be achieved. Advances of combined antiretroviral therapy (cART) in recent years have transformed HIV infection into a chronic disease when treatment is available. However, in spite of the favorable outcomes provided by the newer therapies, cART is not curative and patients are at risk of developing HIV-associated disorders. Moreover, universal access to antiretroviral treatment is restricted by financial obstacles. This review discusses the most recent strategies that have been developed in the search for an HIV cure and to improve life quality of people living with HIV.
    Virology 04/2014; 454-455. DOI:10.1016/j.virol.2014.02.021 · 3.28 Impact Factor
  • Source
    • "Clinical trials have supported the use of chloroquine to reduce immune activation in HIV-infected patients. When chloroquine was administered to ART-naïve subjects for 2 months, patients showed immunological improvement, as the frequency of CD38+ HLA-DR + CD8+ T cells, proliferation of T cells, and circulating LPS levels were signi fi cantly reduced (Murray et al. 2010 ) . Six months of chloroquine administration to HIV-infected clinical nonresponders, who had inadequate reconstitution of CD4+ T cells despite suppressive ART, had decreased frequency of activated T cells, decreased circulating LPS, decreased production of in fl ammatory cytokines (IL-6, TNF-alpha) in response to ex vivo stimulation of TLR ligands, and evidenced improved CD4+ T cell counts and pDC numbers (Piconi et al. 2011 ) . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Plasmacytoid dendritic cells (pDCs) are innate immune cells that are specialized to produce interferon-alpha (IFNα) and participate in activating adaptive immune responses. Although IFNα inhibits HIV-1 (HIV) replication in vitro, pDCs may act as inflammatory and immunosuppressive dendritic cells (DCs) rather than classical antigen-presenting cells during chronic HIV infection in vivo, contributing more to HIV pathogenesis than to protection. Improved understanding of HIV-pDC interactions may yield potential new avenues of discovery to prevent HIV transmission, to blunt chronic immune activation and exhaustion, and to enhance beneficial adaptive immune responses. In this chapter we discuss pDC biology, including pDC development from progenitors, trafficking and localization of pDCs in the body, and signaling pathways involved in pDC activation. We focus on the role of pDCs in HIV transmission, chronic disease progression and immune activation, and immunosuppression through regulatory T cell development. Lastly, we discuss potential future directions for the field which are needed to strengthen our current understanding of the role of pDCs in HIV transmission and pathogenesis.
    Advances in Experimental Medicine and Biology 01/2013; 762:71-107. DOI:10.1007/978-1-4614-4433-6_3 · 2.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A robust animal model for "hypothesis-testing/mechanistic" research in human immunology and immuno-pathology should meet the following criteria. First, it has well-studied hemato-lymphoid organs and target cells similar to those of humans. Second, the human pathogens establish infection and lead to relevant diseases. Third, it is genetically inbred and can be manipulated via genetic, immunological and pharmacological means. Many human-tropic pathogens such as HIV-1 fail to infect murine cells due to the blocks at multiple steps of their life cycle. The mouse with a reconstituted human immune system and other human target organs is a good candidate. A number of human-mouse chimeric models with human immune cells have been developed in the past 20 years, but most with only limited success due to the selective engraftment of xeno-reactive human T cells in hu-PBL-SCID mice or the lack of significant human immune responses in the SCID-hu Thy/Liv mouse. This review summarizes the current understanding of HIV-1 immuno-pathogenesis in human patients and in SIV-infected primate models. It also reviews the recent progress in the development of humanized mouse models with a functional human immune system, especially the recent progress in the immunodeficient mice that carry a defective gammaC gene. NOD/SCID/gammaC(-/-) (NOG or NSG) or the Rag2(-/-)gammaC(-/-) double knockout (DKO) mice, which lack NK as well as T and B cells (NTB-null mice), have been used to reconstitute a functional human immune system in central and peripheral lymphoid organs with human CD34(+) HSC. These NTB-hu HSC humanized models have been used to investigate HIV-1 infection, immuno-pathogenesis and therapeutic interventions. Such models, with further improvements, will contribute to study human immunology, human-tropic pathogens as well as human stem cell biology in the tissue development and function in vivo.
    Science China. Life sciences 02/2010; 53(2):195-203. DOI:10.1007/s11427-010-0059-7 · 1.51 Impact Factor
Show more